- Home
- EWTX vs LSPD Comparison
EWTX vs LSPD Comparison
Compare EWTX & LSPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- LSPD
- Stock Information
- Founded
- EWTX 2017
- LSPD 2005
- Country
- EWTX United States
- LSPD Canada
- Employees
- EWTX N/A
- LSPD N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- LSPD
- Sector
- EWTX Health Care
- LSPD
- Exchange
- EWTX Nasdaq
- LSPD Nasdaq
- Market Cap
- EWTX 1.5B
- LSPD 1.6B
- IPO Year
- EWTX 2021
- LSPD 2020
- Fundamental
- Price
- EWTX $13.93
- LSPD $12.20
- Analyst Decision
- EWTX Buy
- LSPD Buy
- Analyst Count
- EWTX 8
- LSPD 13
- Target Price
- EWTX $41.13
- LSPD $14.04
- AVG Volume (30 Days)
- EWTX 633.0K
- LSPD 706.7K
- Earning Date
- EWTX 08-07-2025
- LSPD 07-31-2025
- Dividend Yield
- EWTX N/A
- LSPD N/A
- EPS Growth
- EWTX N/A
- LSPD N/A
- EPS
- EWTX N/A
- LSPD N/A
- Revenue
- EWTX N/A
- LSPD $1,115,677,000.00
- Revenue This Year
- EWTX N/A
- LSPD $12.92
- Revenue Next Year
- EWTX N/A
- LSPD $13.82
- P/E Ratio
- EWTX N/A
- LSPD N/A
- Revenue Growth
- EWTX N/A
- LSPD 15.46
- 52 Week Low
- EWTX $10.60
- LSPD $7.34
- 52 Week High
- EWTX $38.12
- LSPD $18.96
- Technical
- Relative Strength Index (RSI)
- EWTX 52.63
- LSPD 47.86
- Support Level
- EWTX $12.30
- LSPD $11.91
- Resistance Level
- EWTX $14.11
- LSPD $12.39
- Average True Range (ATR)
- EWTX 0.73
- LSPD 0.53
- MACD
- EWTX 0.00
- LSPD -0.13
- Stochastic Oscillator
- EWTX 53.80
- LSPD 13.71
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About LSPD Lightspeed Commerce Inc. Subordinate Voting Shares
Lightspeed Commerce Inc provides an omni-channel commerce-enabling SaaS platform. Its software platform provides customers with the functionality it needs to engage with consumers, manage their operations, accept payments, and grow their businesses. The company sells its platform through a direct sales force in the United States, Canada, United Kingdom, Australia, and other countries. It derives a majority of its revenue from the United States.